Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105, 3087–3093 (2005). Article CAS PubMed Google Scholar Brocker, T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in ...
The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells ...
Cancer immunotherapy has gained attention as the supreme therapeutic modality for the treatment of various malignancies. Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeutic approach, which seeks to harness the potential of combating cancer cells by using autologo...
The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune...
cancer therapy; immune checkpoints; immunotherapy; CAR-T cells Graphical Abstract1. Introduction Cancer is the second-largest reason for mortality after cardiac disease, with a world incidence and mortality of about 14.1 million and 8.2 million deaths per year, respectively [1]. This disease is ...
how to best harness the anti-cancer abilities of γδ T cells and n-BP for the treatment and prevention of cancermetastasis. In this chapter we provide an overview of the major breakthroughs of this unique immunotherapeutic strategy which may be the most promising immune approach yet for bone...
Therefore, replacement of the TCR variable region with the variable fragment (Fv) of a monoclonal antibody is expected to induce a stronger signal in T cells. Indeed, such chimeric T cell receptors (cTCRs) successfully form TCR complexes, recognize their ligands, and induce IL-2 production and...
Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and costimulatory domains are used to reprogram T-cells to target tumor ce
[23] Faitschuk E, Nagy V, Hombach A A, et al. A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv[J]. Gene T...
(2007), this study shows that expression of PD1 on tumour-infiltrating T cells and PD1 ligands on tumours are poor prognostic markers in various cancers. CAS PubMed Google Scholar Hargadon, K. M., Johnson, C. E. & Williams, C. J. Immune checkpoint blockade therapy for cancer: an ...